Eisai, Biogen battered by controversy over PhII Alzheimer's study after posting positive results
At first blush, Eisai and Biogen posted the kind of promising data for BAN2401 that might have overcome some doubts about its potential as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
